<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36139039</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1200</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom12091200</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are related neurodegenerative disorders displaying substantial overlay, although there are substantial differences at the molecular level. Currently, there is no effective treatment for these diseases. The transcription factor NRF2 has been postulated as a promising therapeutic target as it is capable of modulating key pathogenic events affecting cellular homeostasis. However, there is little experimental evidence on the status of this pathway in both ALS and FTD. Therefore, in this work, we wanted to carry out an exhaustive analysis of this signaling pathway in both transgenic mouse models (ALS and FTD) and human samples from patients with sporadic ALS (sALS) versus controls. In samples from patients with sALS and in the transgenic model with overexpression of TDP-43<sup>A315T</sup>, we observed a significant increase in the NRF2/ARE pathway in the motor cortex and the spinal cord, indicating that NRF2 antioxidant signaling was being induced, but it was not enough to reach cellular homeostasis. On the other hand, in the transgenic FTD model with overexpression of the TDP-43<sup>WT</sup> protein in forebrain neurons, a significantly decreased expression of NQO1 in the prefrontal cortex was seen, which cannot be attributed to alterations in the NRF2 pathway. Our results show that NRF2 signature is differently affected for ALS and FTD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lastres-Becker</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-4968-2175</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, School of Medicine, Institute Te&#xf3;filo Hernando for Drug Discovery, Instituto de Investigaciones Biom&#xe9;dicas "Alberto Sols" UAM-CSIC, Universidad Aut&#xf3;noma de Madrid, Arturo Duperier 4, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lago</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6260-3777</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense and Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2707-8110</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas, Consejo Superior de Investigaciones Cient&#xed;ficas CSIC. Ramiro de Maeztu 9, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Ruiz</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4490-0604</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense and Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">HO-1</Keyword><Keyword MajorTopicYN="N">NQO1</Keyword><Keyword MajorTopicYN="N">NRF2</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36139039</ArticleId><ArticleId IdType="pmc">PMC9496161</ArticleId><ArticleId IdType="doi">10.3390/biom12091200</ArticleId><ArticleId IdType="pii">biom12091200</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gao F.B., Almeida S., Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. EMBO J. 2017;36:2931&#x2013;2950. doi: 10.15252/embj.201797568.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797568</ArticleId><ArticleId IdType="pmc">PMC5641681</ArticleId><ArticleId IdType="pubmed">28916614</ArticleId></ArticleIdList></Reference><Reference><Citation>Couratier P., Corcia P., Lautrette G., Nicol M., Marin B. ALS and frontotemporal dementia belong to a common disease spectrum. Rev. Neurol. 2017;173:273&#x2013;279. doi: 10.1016/j.neurol.2017.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.04.001</ArticleId><ArticleId IdType="pubmed">28449882</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon Y.A., Fratta P., Traynor B.J., Chia R. The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front. Neurosci. 2020;14:42. doi: 10.3389/fnins.2020.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic R.M., Grinberg L.T., Zidar J., Gitcho M.A., Cairns N.J. ALS and FTLD: Two faces of TDP-43 proteinopathy. Eur. J. Neurol. 2008;15:772&#x2013;780. doi: 10.1111/j.1468-1331.2008.02195.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2008.02195.x</ArticleId><ArticleId IdType="pmc">PMC2801606</ArticleId><ArticleId IdType="pubmed">18684309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter E.L., Chen H.-J., Shaw C.E. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurother. J. Am. Soc. Exp. NeuroTher. 2015;12:352&#x2013;363. doi: 10.1007/s13311-015-0338-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0338-x</ArticleId><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Koren S.A., Galvis-Escobar S., Abisambra J.F. Tau-mediated dysregulation of RNA: Evidence for a common molecular mechanism of toxicity in frontotemporal dementia and other tauopathies. Neurobiol. Dis. 2020;141:104939. doi: 10.1016/j.nbd.2020.104939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104939</ArticleId><ArticleId IdType="pmc">PMC7397812</ArticleId><ArticleId IdType="pubmed">32413399</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanchin C., Camuzat A., Campion D., Verpillat P., Hannequin D., Dubois B., Saugier-Veber P., Martin C., Penet C., Charbonnier F., et al. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum. Mol. Genet. 1998;7:1825&#x2013;1829. doi: 10.1093/hmg/7.11.1825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/7.11.1825</ArticleId><ArticleId IdType="pubmed">9736786</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkova-Kostova A.T., Kostov R.V., Kazantsev A.G. The role of Nrf2 signaling in counteracting neurodegenerative diseases. FEBS J. 2018;285:3576&#x2013;3590. doi: 10.1111/febs.14379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.14379</ArticleId><ArticleId IdType="pmc">PMC6221096</ArticleId><ArticleId IdType="pubmed">29323772</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A. Brain-Protective Mechanisms of Transcription Factor NRF2: Toward a Common Strategy for Neurodegenerative Diseases. Annu. Rev. Pharmacol. Toxicol. 2022;62:255&#x2013;277. doi: 10.1146/annurev-pharmtox-052220-103416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-052220-103416</ArticleId><ArticleId IdType="pubmed">34637322</ArticleId></ArticleIdList></Reference><Reference><Citation>Minj E., Yadav R.K., Mehan S. Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders. Curr. Mol. Med. 2021;21:630&#x2013;644. doi: 10.2174/1566524021666210111104920.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1566524021666210111104920</ArticleId><ArticleId IdType="pubmed">33430731</ArticleId></ArticleIdList></Reference><Reference><Citation>Bono S., Feligioni M., Corbo M. Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy. Mol. Neurodegener. 2021;16:71. doi: 10.1186/s13024-021-00479-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00479-8</ArticleId><ArticleId IdType="pmc">PMC8521937</ArticleId><ArticleId IdType="pubmed">34663413</ArticleId></ArticleIdList></Reference><Reference><Citation>Boas S.M., Joyce K.L., Cowell R.M. The NRF2-Dependent Transcriptional Regulation of Antioxidant Defense Pathways: Relevance for Cell Type-Specific Vulnerability to Neurodegeneration and Therapeutic Intervention. Antioxidants. 2021;11:8. doi: 10.3390/antiox11010008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox11010008</ArticleId><ArticleId IdType="pmc">PMC8772787</ArticleId><ArticleId IdType="pubmed">35052512</ArticleId></ArticleIdList></Reference><Reference><Citation>Arslanbaeva L., Bisaglia M. Activation of the Nrf2 Pathway as a Therapeutic Strategy for ALS Treatment. Molecules. 2022;27:1471. doi: 10.3390/molecules27051471.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27051471</ArticleId><ArticleId IdType="pmc">PMC8911691</ArticleId><ArticleId IdType="pubmed">35268572</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzen S., Tucci P., Profumo E., Buttari B., Saso L. A Pivotal Role of Nrf2 in Neurodegenerative Disorders: A New Way for Therapeutic Strategies. Pharmaceuticals. 2022;15:692. doi: 10.3390/ph15060692.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15060692</ArticleId><ArticleId IdType="pmc">PMC9227112</ArticleId><ArticleId IdType="pubmed">35745610</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13:76&#x2013;86. doi: 10.1101/gad.13.1.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.13.1.76</ArticleId><ArticleId IdType="pmc">PMC316370</ArticleId><ArticleId IdType="pubmed">9887101</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., Oyake T., Hayashi N., Satoh K., Hatayama I., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 1997;236:313&#x2013;322. doi: 10.1006/bbrc.1997.6943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1997.6943</ArticleId><ArticleId IdType="pubmed">9240432</ArticleId></ArticleIdList></Reference><Reference><Citation>Baird L., Yamamoto M. The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway. Mol. Cell. Biol. 2020;40:e00099-20. doi: 10.1128/MCB.00099-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00099-20</ArticleId><ArticleId IdType="pmc">PMC7296212</ArticleId><ArticleId IdType="pubmed">32284348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I., Garcia-Yague A.J., Scannevin R.H., Casarejos M.J., Kugler S., Rabano A., Cuadrado A. Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson&#x2019;s Disease. Antioxid. Redox Signal. 2016;25:61&#x2013;77. doi: 10.1089/ars.2015.6549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2015.6549</ArticleId><ArticleId IdType="pmc">PMC4943471</ArticleId><ArticleId IdType="pubmed">27009601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A., Kugler S., Lastres-Becker I. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biol. 2018;14:522&#x2013;534. doi: 10.1016/j.redox.2017.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.10.010</ArticleId><ArticleId IdType="pmc">PMC5681345</ArticleId><ArticleId IdType="pubmed">29121589</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomprezzi R. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: An overview. Ther. Adv. Neurol. Disord. 2015;8:20&#x2013;30. doi: 10.1177/1756285614564152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285614564152</ArticleId><ArticleId IdType="pmc">PMC4286944</ArticleId><ArticleId IdType="pubmed">25584071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I., Innamorato N.G., Jaworski T., Rabano A., Kugler S., Van Leuven F., Cuadrado A. Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain. 2014;137:78&#x2013;91. doi: 10.1093/brain/awt323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt323</ArticleId><ArticleId IdType="pubmed">24277722</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai K.J., Yang C.H., Fang Y.H., Cho K.H., Chien W.L., Wang W.T., Wu T.W., Lin C.P., Fu W.M., Shen C.K. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J. Exp. Med. 2010;207:1661&#x2013;1673. doi: 10.1084/jem.20092164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20092164</ArticleId><ArticleId IdType="pmc">PMC2916125</ArticleId><ArticleId IdType="pubmed">20660618</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I., Bell S., Cairns N.J., Miller T.M., Baloh R.H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal&#xe1;n-Ganga M., Rodr&#xed;guez-Cueto C., Merch&#xe1;n-Rubira J., Hern&#xe1;ndez F., &#xc1;vila J., Posada-Ayala M., Lanciego J.L., Luengo E., Lopez M.G., R&#xe1;bano A., et al. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. Acta Neuropathol. Commun. 2021;9:90. doi: 10.1186/s40478-021-01196-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01196-5</ArticleId><ArticleId IdType="pmc">PMC8130522</ArticleId><ArticleId IdType="pubmed">34001284</ArticleId></ArticleIdList></Reference><Reference><Citation>Erben L., Buonanno A. Detection and Quantification of Multiple RNA Sequences Using Emerging Ultrasensitive Fluorescent In Situ Hybridization Techniques. Curr. Protoc. Neurosci. 2019;87:e63. doi: 10.1002/cpns.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpns.63</ArticleId><ArticleId IdType="pmc">PMC7476812</ArticleId><ArticleId IdType="pubmed">30791216</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia E., Limon D., Perez-De La Cruz V., Giordano M., Diaz-Mu&#xf1;oz M., Maldonado P.D., Herrera-Mundo M.N., Pedraza-Chaverri J., Santamaria A. Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: Protective role of S-allylcysteine. Free Radic. Res. 2008;42:892&#x2013;902. doi: 10.1080/10715760802506356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10715760802506356</ArticleId><ArticleId IdType="pubmed">18985488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I., Porras G., Arribas-Bl&#xe1;zquez M., Maestro I., Borrego-Hern&#xe1;ndez D., Boya P., Cerd&#xe1;n S., Garc&#xed;a-Redondo A., Mart&#xed;nez A., Martin-Requero &#xc1;. Molecular Alterations in Sporadic and SOD1-ALS Immortalized Lymphocytes: Towards a Personalized Therapy. Int. J. Mol. Sci. 2021;22:3007. doi: 10.3390/ijms22063007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22063007</ArticleId><ArticleId IdType="pmc">PMC8000750</ArticleId><ArticleId IdType="pubmed">33809456</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T.J., Lee V.M., Trojanowski J.Q. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med. 2011;17:659&#x2013;667. doi: 10.1016/j.molmed.2011.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2011.06.004</ArticleId><ArticleId IdType="pmc">PMC3202652</ArticleId><ArticleId IdType="pubmed">21783422</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross D., Siegel D. Functions of NQO1 in Cellular Protection and CoQ10 Metabolism and its Potential Role as a Redox Sensitive Molecular Switch. Front. Physiol. 2017;8:595. doi: 10.3389/fphys.2017.00595.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2017.00595</ArticleId><ArticleId IdType="pmc">PMC5573868</ArticleId><ArticleId IdType="pubmed">28883796</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho M.A., Baloh R.H., Chakraverty S., Mayo K., Norton J.B., Levitch D., Hatanpaa K.J., White C.L., 3rd, Bigio E.H., Caselli R., et al. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 2008;63:535&#x2013;538. doi: 10.1002/ana.21344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21344</ArticleId><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Cueto C., G&#xf3;mez-Almer&#xed;a M., Garc&#xed;a Toscano L., Romero J., Hillard C.J., de Lago E., Fern&#xe1;ndez-Ruiz J. Inactivation of the CB(2) receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis. Brain Pathol. 2021;31:e12972. doi: 10.1111/bpa.12972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12972</ArticleId><ArticleId IdType="pmc">PMC8549023</ArticleId><ArticleId IdType="pubmed">33983653</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M., Gunay A., Chandel N.S., Ozdinler P.H. Mitochondrial dysregulation occurs early in ALS motor cortex with TDP-43 pathology and suggests maintaining NAD+ balance as a therapeutic strategy. Sci. Rep. 2022;12:4287. doi: 10.1038/s41598-022-08068-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-08068-5</ArticleId><ArticleId IdType="pmc">PMC8917163</ArticleId><ArticleId IdType="pubmed">35277554</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlette A., Krampfl K., Grothe C., Neuhoff N., Dengler R., Petri S. Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2008;67:1055&#x2013;1062. doi: 10.1097/NEN.0b013e31818b4906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31818b4906</ArticleId><ArticleId IdType="pubmed">18957896</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E., Factor-Litvak P., Santella R.M., Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2013;65:509&#x2013;527. doi: 10.1016/j.freeradbiomed.2013.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.06.029</ArticleId><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H., Santella R.M., Liu X., Bogdanov M., Zipprich J., Wu H.-C., Mahata J., Kilty M., Bednarz K., Bell D., et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph. Lateral Scler. 2008;9:177&#x2013;183. doi: 10.1080/17482960801933942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960801933942</ArticleId><ArticleId IdType="pmc">PMC4332387</ArticleId><ArticleId IdType="pubmed">18574762</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Gonz&#xe1;lez L., Rodr&#xed;guez-Cueto C., Cabezudo D., Bartolom&#xe9; F., Andr&#xe9;s-Benito P., Ferrer I., Gil C., Mart&#xed;n-Requero &#xc1;., Fern&#xe1;ndez-Ruiz J., Mart&#xed;nez A., et al. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1&#x3b4; kinase inhibitor treatment. Sci. Rep. 2020;10:4449. doi: 10.1038/s41598-020-61265-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-61265-y</ArticleId><ArticleId IdType="pmc">PMC7064575</ArticleId><ArticleId IdType="pubmed">32157143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-C&#xe1;mara O., Arribas M., Wells G., Morales-Tenorio M., Mart&#xed;n-Requero &#xc1;., Porras G., Mart&#xed;nez A., Giorgi G., L&#xf3;pez-Alvarado P., Lastres-Becker I., et al. Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis. J. Med. Chem. 2022;65:1867&#x2013;1882. doi: 10.1021/acs.jmedchem.1c01255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c01255</ArticleId><ArticleId IdType="pmc">PMC9132363</ArticleId><ArticleId IdType="pubmed">34985276</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergstr&#xf6;m P., von Otter M., Nilsson S., Nilsson A.C., Nilsson M., Andersen P.M., Hammarsten O., Zetterberg H. Association of NFE2L2 and KEAP1 haplotypes with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2014;15:130&#x2013;137. doi: 10.3109/21678421.2013.839708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.839708</ArticleId><ArticleId IdType="pubmed">24102512</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Fabuel I., Le Douce J., Logan A., James A.M., Bonvento G., Murphy M.P., Almeida A., Bola&#xf1;os J.P. Complex I assembly into supercomplexes determines differential mitochondrial ROS production in neurons and astrocytes. Proc. Natl. Acad. Sci. USA. 2016;113:13063&#x2013;13068. doi: 10.1073/pnas.1613701113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1613701113</ArticleId><ArticleId IdType="pmc">PMC5135366</ArticleId><ArticleId IdType="pubmed">27799543</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicente-Gutierrez C., Bonora N., Jimenez-Blasco D., Lopez-Fabuel I., Bates G., Murphy M.P., Almeida A., Bola&#xf1;os J.P. Abrogating mitochondrial ROS in neurons or astrocytes reveals cell-specific impact on mouse behaviour. Redox Biol. 2021;41:101917. doi: 10.1016/j.redox.2021.101917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2021.101917</ArticleId><ArticleId IdType="pmc">PMC7972977</ArticleId><ArticleId IdType="pubmed">33711713</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I., Ulusoy A., Innamorato N.G., Sahin G., R&#xe1;bano A., Kirik D., Cuadrado A. &#x3b1;-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson&#x2019;s disease. Hum. Mol. Genet. 2012;21:3173&#x2013;3192. doi: 10.1093/hmg/dds143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds143</ArticleId><ArticleId IdType="pubmed">22513881</ArticleId></ArticleIdList></Reference><Reference><Citation>Zgorzynska E., Dziedzic B., Walczewska A. An Overview of the Nrf2/ARE Pathway and Its Role in Neurodegenerative Diseases. Int. J. Mol. Sci. 2021;22:9592. doi: 10.3390/ijms22179592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179592</ArticleId><ArticleId IdType="pmc">PMC8431732</ArticleId><ArticleId IdType="pubmed">34502501</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes Diaz G., Hupperts R., Fraussen J., Somers V. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. Autoimmun. Rev. 2018;17:1240&#x2013;1250. doi: 10.1016/j.autrev.2018.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.07.001</ArticleId><ArticleId IdType="pubmed">30316988</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas M.R., Johnson D.A., Sirkis D.W., Messing A., Johnson J.A. Nrf2 Activation in Astrocytes Protects against Neurodegeneration in Mouse Models of Familial Amyotrophic Lateral Sclerosis. J. Neurosci. 2008;28:13574&#x2013;13581. doi: 10.1523/JNEUROSCI.4099-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4099-08.2008</ArticleId><ArticleId IdType="pmc">PMC2866507</ArticleId><ArticleId IdType="pubmed">19074031</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas M.R., Burton N.C., Kutzke J., Gan L., Johnson D.A., Sch&#xe4;fer M., Werner S., Johnson J.A. Absence of Nrf2 or its selective overexpression in neurons and muscle does not affect survival in ALS-linked mutant hSOD1 mouse models. PLoS ONE. 2013;8:e56625. doi: 10.1371/annotation/28f68b10-e23d-4519-8d52-8cc94fe372b1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/annotation/28f68b10-e23d-4519-8d52-8cc94fe372b1</ArticleId><ArticleId IdType="pmc">PMC3572065</ArticleId><ArticleId IdType="pubmed">23418589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau A., Tian W., Whitman S.A., Zhang D.D. The predicted molecular weight of Nrf2: It is what it is not. Antioxid. Redox Signal. 2013;18:91&#x2013;93. doi: 10.1089/ars.2012.4754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.4754</ArticleId><ArticleId IdType="pmc">PMC3503463</ArticleId><ArticleId IdType="pubmed">22703241</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby J., Halligan E., Baptista M.J., Allen S., Heath P.R., Holden H., Barber S.C., Loynes C.A., Wood-Allum C.A., Lunec J., et al. Mutant SOD1 alters the motor neuronal transcriptome: Implications for familial ALS. Brain. 2005;128:1686&#x2013;1706. doi: 10.1093/brain/awh503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh503</ArticleId><ArticleId IdType="pubmed">15872021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimoto T., Miyazaki K., Morimoto N., Kurata T., Satoh K., Ikeda Y., Abe K. Impaired antioxydative Keap1/Nrf2 system and the downstream stress protein responses in the motor neuron of ALS model mice. Brain Res. 2012;1446:109&#x2013;118. doi: 10.1016/j.brainres.2011.12.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.12.064</ArticleId><ArticleId IdType="pubmed">22353756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R.A., Rademakers R. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr. Opin. Neurol. 2008;21:693&#x2013;700. doi: 10.1097/WCO.0b013e3283168d1d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e3283168d1d</ArticleId><ArticleId IdType="pmc">PMC2869081</ArticleId><ArticleId IdType="pubmed">18989115</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy J.M., Henry R.G., Langmore S., Kramer J.H., Miller B.L., Lomen-Hoerth C. Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch. Neurol. 2007;64:530&#x2013;534. doi: 10.1001/archneur.64.4.530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.4.530</ArticleId><ArticleId IdType="pubmed">17420314</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C., Anderson T., Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077&#x2013;1079. doi: 10.1212/WNL.59.7.1077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.59.7.1077</ArticleId><ArticleId IdType="pubmed">12370467</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo-Porras F., Garc&#xed;a-Toscano L., Rodr&#xed;guez-Cueto C., Santos-Garc&#xed;a I., de Lago E., Fernandez-Ruiz J. Targeting glial cannabinoid CB(2) receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Br. J. Pharmacol. 2019;176:1585&#x2013;1600. doi: 10.1111/bph.14216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14216</ArticleId><ArticleId IdType="pmc">PMC6487601</ArticleId><ArticleId IdType="pubmed">29574689</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujalled D., Grubman A., Acevedo K., Yang S., Ke Y.D., Moujalled D.M., Duncan C., Caragounis A., Perera N.D., Turner B.J., et al. TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Hum. Mol. Genet. 2017;26:1732&#x2013;1746. doi: 10.1093/hmg/ddx093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx093</ArticleId><ArticleId IdType="pubmed">28334913</ArticleId></ArticleIdList></Reference><Reference><Citation>Young J.J., Lavakumar M., Tampi D., Balachandran S., Tampi R.R. Frontotemporal dementia: Latest evidence and clinical implications. Adv. Psychopharmacol. 2018;8:33&#x2013;48. doi: 10.1177/2045125317739818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2045125317739818</ArticleId><ArticleId IdType="pmc">PMC5761910</ArticleId><ArticleId IdType="pubmed">29344342</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>